Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICX-RHY phase IIa open-label dose-escalation study for nasolabial folds
2006-003639-59Phase 2Completed
- Sponsor
- Intercytex Group
- Start
- Dec 2006
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ICX-RHY-013 in wrinkle and nasolabial fold, sponsored by Intercytex Group. Primary endpoint: Clinical change in nasolabial fold severity. Started Dec 2006; status: completed.
02
Drugs
ICX-RHY-013
03
Conditions
wrinklenasolabial fold
Beyond the preview
Go deeper on 2006-003639-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003639-59.